Cybersecurity Selloff, $CB Investment Case, $ACLX Buyout, and More
Welcome back to the BBAE Blog, your trusted source for the latest investment insights and analyses from the BBAE team. This week, we’re excited to share some highlights that will keep you informed and ahead of the market. Don’t forget, some of our most valuable insights are available exclusively in the BBAE Pro app—download it now to unlock full access!
- AI Disruption Fears Hit Cybersecurity Stocks
- Wedgewood Partners: Chubb ($CB) Investment Case
- Trending Tickers: $ACLX Buyout, $CLVT Unit Sale Talks, $FRMI Texas Permit
Need a reminder of why BBAE? We have one goal: to provide you with exclusive content and data to help you make informed investing decisions. Explore a wealth of market insights and potential investing opportunities that you can’t find anywhere else.
AI Disruption Fears Hit Cybersecurity Stocks
Anthropic’s launch of Claude Code Security, a built-in AI code scanning feature, triggered a sharp two-day selloff in cybersecurity stocks as investors reassessed how quickly large language models could expand into traditional security workflows. Even though the tool is in limited preview and requires human oversight, markets reacted to the broader implication that AI coding platforms may begin absorbing functions historically handled by standalone security vendors. The move fits a wider early-2026 pattern in which new AI feature announcements have driven rapid repricing across software sectors, reflecting heightened sensitivity to potential long-term disruption. Read the full article here.
Wedgewood Partners: Chubb ($CB) Investment Case
In their Q4 2025 investor letter, Wedgewood Partners introduces Chubb ($CB), a global property and casualty insurance leader specializing in “non-standard” products for high-net-worth clients and mid-sized businesses. Founded in 1882, Chubb demonstrates best-in-class underwriting with a 10-year combined ratio of 89.8% versus peers’ 97.8%, while avoiding commodity-like, price-driven markets. The company’s diversified business lines, hundreds of risk consultants, and growing investment portfolio ($166B in Q3 2025) support consistent double-digit earnings growth. Wedgewood believes Chubb’s superior underwriting discipline, independence from single insurance cycles, and rising investment returns will continue delivering attractive profitability. Read the full article here.
Trending Tickers: $ACLX Buyout, $CLVT Unit Sale Talks, $FRMI Texas Permit
This week, several stocks attracted attention due to major developments. Here’s a breakdown:
- Arcellx ($ACLX): Gilead agreed to acquire Arcellx for about $7.8B, offering $115 per share in cash plus a contingent value right of up to $5 tied to future sales milestones. According to Gilead, the deal gives it full control of anito-cel, a CAR-T therapy under FDA review for multiple myeloma. Shares surged 77% to near the deal price.
- Clarivate ($CLVT): Clarivate said it is exploring a sale of its Life Sciences & Healthcare unit as part of a strategic review. According to the company, proceeds could help reduce leverage and sharpen focus on its core businesses. Shares jumped nearly 40% following the announcement.
- Fermi Inc. ($FRMI): Fermi secured final approval of a Clean Air Permit in Texas for natural gas power generation at its Project Matador campus. According to the company, the permit clears a major regulatory hurdle for building a large private power grid designed to serve AI and industrial customers. Shares rose about 17% on the news.
Read the full Weekly Highlights article here.
This article is for informational purposes only and is neither investment advice nor a solicitation to buy or sell securities. All investment involves inherent risks, including the total loss of principal, and past performance is not a guarantee of future results. Always conduct thorough research or consult with a financial expert before making any investment decisions. BBAE has no position in any investment mentioned.
